Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DRUG Bright Minds Biosciences	$23.27 -6.1%	$29.56	$0.93 ▼ $79.02	$163.82M	-5.74	828,351 shs	627,261 shs
FHTX Foghorn Therapeutics	$4.84 -0.4%	$4.37	$2.94 ▼ $10.25	$269.78M	3.05	142,780 shs	870,126 shs
IMMP Prima BioMed	$1.64 +0.6%	$1.80	$1.32 ▼ $2.72	$239.51M	1.76	194,370 shs	56,504 shs
MGX Metagenomi	$1.46 -8.2%	$1.60	$1.23 ▼ $5.50	$54.58M	-0.34	837,415 shs	3.61 million shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DRUG Bright Minds Biosciences	0.00%	-14.79%	-10.50%	-35.49%	+2,045.49%
FHTX Foghorn Therapeutics	0.00%	+2.54%	+16.91%	+32.60%	-15.83%
IMMP Prima BioMed	0.00%	+2.50%	-14.14%	-6.82%	-18.41%
MGX Metagenomi	0.00%	+0.69%	-13.62%	+7.35%	-64.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DRUG Bright Minds Biosciences	3.1825 of 5 stars	3.6	3.0	4.0	2.5	0.0
FHTX Foghorn Therapeutics	2.1026 of 5 stars	3.6	0.0	3.2	1.7	0.6
IMMP Prima BioMed	1.4241 of 5 stars	3.5	1.0	2.7	0.0	0.0
MGX Metagenomi	2.5118 of 5 stars	3.5	2.0	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DRUG Bright Minds Biosciences	3.25	Buy	$83.25	257.76% Upside
FHTX Foghorn Therapeutics	3.13	Buy	$12.13	150.52% Upside
IMMP Prima BioMed	3.00	Buy	$7.00	326.83% Upside
MGX Metagenomi	3.00	Buy	$13.00	790.41% Upside

Current Analyst Ratings Breakdown

Latest MGX, IMMP, DRUG, and FHTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/15/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
5/15/2025	MGX Metagenomi	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $12.00
5/14/2025	MGX Metagenomi	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$20.00 ➝ $16.00
5/14/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	DRUG Bright Minds Biosciences	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/13/2025	DRUG Bright Minds Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	DRUG Bright Minds Biosciences	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/7/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
4/30/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
4/30/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$0.92 per share	N/A
FHTX Foghorn Therapeutics	$22.60M	11.94	N/A	N/A	($0.82) per share	-5.90
IMMP Prima BioMed	$5.14M	46.60	N/A	N/A	$1.05 per share	1.56
MGX Metagenomi	$52.29M	1.04	N/A	N/A	$6.28 per share	0.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DRUG Bright Minds Biosciences	-$2.06M	-$0.36	N/A	N/A	N/A	N/A	-14.56%	-14.29%	8/13/2025 (Estimated)
FHTX Foghorn Therapeutics	-$86.62M	-$1.36	N/A	N/A	N/A	-342.23%	N/A	-27.28%	8/6/2025 (Estimated)
IMMP Prima BioMed	-$28.01M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
MGX Metagenomi	-$78.06M	-$2.11	N/A	N/A	N/A	-172.21%	-31.21%	-22.21%	8/13/2025 (Estimated)

Latest MGX, IMMP, DRUG, and FHTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q2 2025	DRUG Bright Minds Biosciences	-$0.39	-$0.29	+$0.10	-$0.29	N/A	N/A
5/14/2025	Q1 2025	FHTX Foghorn Therapeutics	-$0.30	-$0.30	N/A	-$0.30	$4.96 million	$5.95 million
5/13/2025	Q1 2025	MGX Metagenomi	-$0.62	-$0.68	-$0.06	-$0.68	$8.75 million	$4.13 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DRUG Bright Minds Biosciences	N/A	126.01	126.01
FHTX Foghorn Therapeutics	N/A	3.16	3.16
IMMP Prima BioMed	N/A	18.86	N/A
MGX Metagenomi	N/A	5.85	5.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DRUG Bright Minds Biosciences	40.52%
FHTX Foghorn Therapeutics	61.55%
IMMP Prima BioMed	2.32%
MGX Metagenomi	N/A

Insider Ownership

Company	Insider Ownership
DRUG Bright Minds Biosciences	42.66%
FHTX Foghorn Therapeutics	7.58%
IMMP Prima BioMed	3.07%
MGX Metagenomi	17.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DRUG Bright Minds Biosciences	N/A	7.04 million	4.04 million	Not Optionable
FHTX Foghorn Therapeutics	120	55.74 million	51.52 million	Optionable
IMMP Prima BioMed	2,021	146.04 million	141.56 million	Optionable
MGX Metagenomi	236	37.38 million	30.73 million	N/A

MGX, IMMP, DRUG, and FHTX Headlines

Recent News About These Companies

Metagenomi, Inc. (NASDAQ:MGX) Shares Sold by Millennium Management LLC

June 15, 2025 | marketbeat.com

Insider Selling: Metagenomi, Inc. (NASDAQ:MGX) CEO Sells 10,785 Shares of Stock

June 10, 2025 | insidertrades.com

Metagenomi, Inc. (NASDAQ:MGX) CEO Sells $18,873.75 in Stock

June 9, 2025 | marketbeat.com

Metagenomi, Inc. (NASDAQ:MGX) Short Interest Down 18.9% in May

June 3, 2025 | marketbeat.com

Citadel Advisors LLC Decreases Position in Metagenomi, Inc. (NASDAQ:MGX)

June 2, 2025 | marketbeat.com

Northern Trust Corp Raises Position in Metagenomi, Inc. (NASDAQ:MGX)

May 31, 2025 | marketbeat.com

HC Wainwright Analysts Cut Earnings Estimates for Metagenomi

May 30, 2025 | marketbeat.com

Metagenomi, Inc. (NASDAQ:MGX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

May 16, 2025 | finance.yahoo.com

2MGX : Demystifying Metagenomi: Insights From 4 Analyst Reviews

May 15, 2025 | benzinga.com

Metagenomi Reports Promising Hemophilia A Study Results

May 14, 2025 | tipranks.com

Metagenomi, Inc.: Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

May 14, 2025 | finanznachrichten.de

Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025

May 14, 2025 | globenewswire.com

Metagenomi (MGX) Reports Q1 Loss, Misses Revenue Estimates

May 13, 2025 | zacks.com

Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

May 13, 2025 | globenewswire.com

Metagenomi to Present at Upcoming Scientific Meetings

May 2, 2025 | globenewswire.com

Metagenomi Leads The Charge With These 3 Penny Stocks

April 10, 2025 | uk.finance.yahoo.com

Metagenomi price target lowered to $7 from $14 at H.C. Wainwright

April 4, 2025 | markets.businessinsider.com

Metagenomi, Inc. Common Stock (MGX) Latest After Hours Trades

March 31, 2025 | nasdaq.com

Biotech stocks slide as Marks resignation seen being negative for sector

March 31, 2025 | markets.businessinsider.com

Bullish: Analysts Just Made A Significant Upgrade To Their Metagenomi, Inc. (NASDAQ:MGX) Forecasts

March 27, 2025 | uk.finance.yahoo.com

Metagenomi, Inc.: Metagenomi Reports Business Updates and Full Year 2024 Financial Results

March 19, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
With Novo Nordisk's CEO Out, Wall Street Wants an American Leader
By Leo Miller | June 7, 2025
View With Novo Nordisk's CEO Out, Wall Street Wants an American Leader
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
By Nathan Reiff | June 12, 2025
View Analysts Can't Get Enough of These Little-Known Biopharma Stocks
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
By Leo Miller | June 28, 2025
View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA
By Leo Miller | June 12, 2025
View IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA

MGX, IMMP, DRUG, and FHTX Company Descriptions

Bright Minds Biosciences NASDAQ:DRUG

$23.27 -1.51 (-6.09%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$24.39 +1.12 (+4.83%)

As of 06/27/2025 07:56 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Foghorn Therapeutics NASDAQ:FHTX

$4.84 -0.02 (-0.41%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.84 0.00 (0.00%)

As of 06/27/2025 04:34 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Prima BioMed NASDAQ:IMMP

$1.64 +0.01 (+0.61%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.63 -0.01 (-0.61%)

As of 06/27/2025 07:57 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Metagenomi NASDAQ:MGX

$1.46 -0.13 (-8.18%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.54 +0.08 (+5.48%)

As of 06/27/2025 07:59 PM Eastern

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time